ArticleCureus2022
Signal-Induced Inhibition of Telomerase Activity in HL60 Cancer Cells by Signal Transduction Using the Biophysically Activated Regulative Molecule 31 (RM31): A Pilot Study.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this pilot study, we report the use of a novel, patented biophysical technology, which enables intranuclear access and cell nucleus stimulation, via the signal of the biophysically activated regulative molecule 31 (RM31). RM31 is the name of an isolated natural molecule found in the human body and is involved in many cellular mechanisms. We used a specific low electromagnetic field frequency to activate the RM31 molecule, which leads to specific signal transduction, to investigate the effect of telomerase activity in HL60 cancer cells. Our results revealed a dramatic inhibition in telomerase activity, a 99.5% decrease within 72 hours, with avoidance of subsequent reactivation, due to the simultaneous inhibition of human telomerase reverse transcriptase (hTERT).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.